FDA Classifies HemosIL HIT Antibody Assay Recall as Most Serious in October 2026: Four Lots With Negative Bias Up to 47%

On October 30, 2026, the U.S. Food and Drug Administration (FDA) confirmed on its Medical Device Recalls and Early Alerts page that Instrumentation Laboratories (Werfen) has recalled four lots of the HemosIL AcuStar HIT-IgG(PF4-H) heparin-induced thrombocytopenia (HIT) antibody assay, and classified the recall as the most serious type. The affected lots are B40005, B40006, B38062 and B38063, covering two part numbers. The company's investigation confirmed performance variation in these lots, with negative bias of 20% to 35% in patient samples and a mean negative bias of 47% in one complaint, which routine calibration and quality control may not detect. Results may be reported below the 1.00 U/mL cutoff and read as "antibody negative." FDA requires users to inventory, destroy and document the affected product, and to arrange alternative testing methods in advance because supply interruptions are expected. As of September 3, 2026, the company had not reported related serious injuries or deaths.

Recall and safety notice: an in vitro diagnostic recall classified as the most serious type

On October 30, 2026, FDA updated its Medical Device Recalls and Early Alerts page with a confirmed recall: Instrumentation Laboratories (Werfen) has recalled certain lots of the HemosIL AcuStar HIT-IgG(PF4-H) assay. The page states at the outset that this is the most serious type of recall recognized by FDA — continued use may cause serious injury or death.

This is not an ordinary lot-defect notice. The recalled product is an antibody assay for heparin-induced thrombocytopenia (HIT), and its results directly inform the clinical judgment on whether a patient can continue to receive heparin. An error in the assay itself does not produce an immediate patient reaction, but the treatment decision will be misdirected accordingly.

Affected lots and part numbers

FDA lists the affected products by four lots under two part numbers:

• Part number 0009800127: lots B40005 and B40006, both with an expiration date of January 16, 2027.
• Part number 0009802028: lots B38062 and B38063, both with an expiration date of November 1, 2026.
• The UDIs for the two part numbers are 08426951126545 and 08426950545774, respectively.

All four lots involve the same reagent and the same assay principle. The company's customer notification requires these lots to be removed from locations where they are used or sold, rather than being retained with an additional restriction on use.

The problem is a performance deviation, not a single-lot incident

According to the FDA page, the company received customer complaints reporting invalid calibration curves; in one complaint, patient samples showed a mean negative bias of 47%. The company's investigation confirmed that the affected lots exhibit a negative bias of 20% to 35%, and that this deviation may not be detected by routine calibration and quality control testing. Root cause investigation is still ongoing.

The significance lies in the second part of that statement. Routine calibration and quality control are the laboratory's daily line of defense. If a deviation can bypass that defense, a laboratory's procedural finding of "results within specification" is not sufficient to demonstrate that the reagent is performing correctly. This is also why the required action is destruction rather than continued use with enhanced quality control.

Clinical consequence: false negatives, not false positives

A negative bias means measured values are lower than the true value. The FDA page states that this deviation may cause sample results to be reported below the assay cutoff (1.00 U/mL) and therefore interpreted as "HIT IgG antibody negative."

For patients with a high clinical suspicion of HIT, a single false-negative result may delay recognition and thereby affect management. If a patient with HIT continues to be exposed to heparin, the risk of thrombotic complications increases. Two layers should be distinguished here: a reagent error does not mean that a patient will necessarily experience harm, but an erroneous result will lead the physician toward an incorrect treatment decision, and that chain of events is clear.

As of September 3, 2026, the company had not reported serious injuries or deaths related to this issue. The FDA page also states that decisions on whether previously reported results need to be reviewed and whether patients need follow-up or retesting are left to laboratories and clinicians in accordance with local procedures, clinical judgment and applicable regulations.

Three actions required of users

• First, inventory products corresponding to the four affected lots and destroy them in accordance with the institution's standard procedures.
• Second, record the quantity destroyed and the destruction date on the Urgent Mandatory Response Tracking Form.
• Third, arrange alternative HIT antibody testing methods in advance, because supply interruptions are expected; the company recommends contacting the local Werfen representative for transition support.

The third action is the most easily overlooked. Recall notices are often read as "stop using a certain lot," but here the company itself states that a supply interruption is expected. For laboratories that rely on this platform for HIT testing, an alternative method is not simply a matter of obtaining another kit; it also involves method comparison, reference intervals, reporting conventions and clinical communication.

What the product is

According to the device intended use statement on the FDA page, HemosIL AcuStar HIT-IgG(PF4-H) is a qualitative, fully automated chemiluminescent immunoassay for the detection of IgG antibodies that react with heparin-platelet factor 4 (PF4) complexes. Results are interpreted as positive or negative and, in conjunction with other laboratory and clinical findings, aid in assessing the risk of HIT.

This positioning matters: it is an aid to judgment, not a confirmatory tool. For that reason, a deviation in the assay result does not by itself constitute a diagnosis, but it does genuinely alter the weight of evidence available to the physician.

Why the classification is so severe

FDA placed this recall in the most serious category. The basis for that determination is not whether anyone was injured, but what could result if the product continued to be used. The page expressly states that continued use may cause serious injury or death, and that this is the basis for the intensity of the required action.

For in vitro diagnostic companies, this offers a useful perspective: recall classification turns on the severity of the potential consequence, not on the number of harms that have already occurred. An aid-to-diagnosis reagent may be placed in the highest category whenever an erroneous result could change treatment decisions and the consequence is irreversible.

AIMEILI regulatory interpretation

This enforcement action illustrates several principles that IVD manufacturers should apply when assessing their own post-market risk. First, FDA's Class I designation is a hazard-based determination. It reflects the potential for serious injury or death from continued use, not the confirmed harm count. Manufacturers preparing a health hazard evaluation should therefore assess the worst credible clinical outcome associated with an erroneous result, particularly where the assay informs an irreversible therapeutic decision such as continuation or withdrawal of heparin.

Second, the case highlights the limits of routine calibration and quality control as a defense. Where a performance deviation can evade the laboratory's daily quality control, the appropriate corrective action is removal of the affected product from the market rather than continued use with enhanced QC. Manufacturers should verify that their internal lot-release and stability programs are capable of detecting bias of the magnitude described here, and that investigation of invalid calibration curves is escalated as a potential systemic performance issue rather than handled as an isolated complaint.

Third, the recall notice demonstrates the regulatory expectation of a complete field action: unambiguous lot and part-number identification, UDI traceability, explicit destruction instructions, documented response tracking, and advance notice of supply interruption with a defined path to alternative methods. Manufacturers and their authorized representatives should ensure that customer notifications contain each of these elements, since incomplete field action communications are a frequent subject of regulatory observation.

Finally, the open root cause investigation is itself a compliance consideration. Where a root cause has not been conclusively established at the time of a recall, regulators expect the manufacturer to state that clearly, to continue the investigation under a defined CAPA process, and to commit to further communication. Distributors and regulatory affairs teams should monitor the FDA recall page for updates, including any revision of the lot list or the scope of the action.

Business impact

For IVD manufacturers, this recall underscores that a Class I field action on an aid-to-diagnosis assay can affect the entire commercial relationship with a laboratory customer, not just the affected lots. Laboratories that depend on the platform must validate an alternative method, which involves method comparison, establishment of reference intervals, revision of reporting conventions and clinician communication. Manufacturers of competing assays should anticipate increased demand and be prepared to support validation documentation and technical transfer within compressed timelines.

For distributors and authorized representatives, the immediate operational burden is inventory reconciliation across the four affected lots and both part numbers, quarantine and destruction in line with the manufacturer's instructions, and documented reporting back through the urgent response tracking process. Distributors holding stock in multiple jurisdictions should confirm whether local competent authorities require a separate field safety corrective action notification, since an FDA Class I action frequently triggers corresponding obligations in other markets.

For CROs and contract testing laboratories, the recall creates a chain-of-custody and data integrity issue. Where archived samples or previously reported results are involved, laboratories should document the affected lot numbers used, assess whether reported results require review, and retain records supporting any decision not to retest. Sponsor-facing communication should be proactive, since a change in HIT testing methodology during an ongoing study may require a protocol deviation assessment.

For regulatory affairs teams, the case is a practical benchmark for health hazard evaluation and recall classification strategy. It demonstrates that severity of the potential clinical consequence, the ability of routine quality control to detect the deviation, and the availability of a validated alternative are the factors regulators weigh most heavily. Manufacturers should reflect these factors in their recall SOPs, their complaint trending thresholds and their supplier and lot-release acceptance criteria.

Sources and scope

Source: U.S. Food and Drug Administration (FDA), "Platelet Factor 4 (PF4) Radioimmunoassay Recall: Instrumentation Laboratories Removes HemosIL AcuStar HIT-IgG(PF4-H)," Medical Device Recalls and Early Alerts, updated October 30, 2026, event number 99843.

Source: U.S. Food and Drug Administration (FDA), Medical Device Recalls and Early Alerts listing page; the entry is dated October 30, 2026 and its status is listed as Recall Confirmed.

Verification scope and access date: this review verified the affected product table, required actions, recall reason, device intended use and contact information on the recall detail page, together with the date and status shown on the recall listing page; the recall number and distribution quantities in the FDA Enforcement Report database were not individually cross-checked. Access date: November 1, 2026.

Scope note: this article is an interpretation of publicly available regulatory information. It does not constitute a conclusion or commitment regarding any specific product, company or testing method, and it is not clinical advice. The lot范围, bias values and required actions are governed by the original FDA and company notices, and the information may change with subsequent official updates.